Reimbursement,

20.07.2020

DiGA consultation meetings: Prescription and use

What we took from the last online meeting with the hih of the Federal Ministry of Health? Here is a short and concise summary:

The BfArM has held consultation meetings with about 50 DiGA manufacturers and received 14 applications for inclusion in the DiGA directory (as of 16.07.20). At the end of August 2020, the first DiGAs that are listed in the directory can be expected. For the time being, the ordinance will be based on "Muster 16"; the basis for use and invoicing will be a 16-digit prescription code. Price negotiations will be held between the manufacturer and the GKV-SV after successful #evaluation. Relevant principles on pricing and remuneration are regulated in the framework agreement and billing guidelines.

More information is available at in our German speaking sites.

Market Access,

10.06.2020

Regular reimbursement for medical apps in Germany

With the Digital Care Act (DVG), structures were created to establish regular reimbursement for digital health applications (DiGA) in Germany. What evidence is necessary to convince the Federal Institute for Drugs and Medical Devices (BfArM)? How do I effectively conduct a consultation with the authority and what are the minimum requirements for an evaluation concept? We answer these and other questions based on our first experiences with the new regulations and, if necessary, we will be happy to network with our customers. Request a catalogue of criteria and further practical informatio or learn more on DiGA in the German market

Patient Preferences for Treatment of pNP: Findings From a Survey Using the Discrete Choice Experiment Methodology

Real World Evidence, Evidence Generation

11.02.2021

A brief video summary of our latest study using a Discrete Choice Experiment (DCE); health services research: